<DOC>
	<DOC>NCT01310400</DOC>
	<brief_summary>A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V is as immunogenic as a locally sourced competitor vaccine in young children.</brief_summary>
	<brief_title>Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>≥6months to ≤35 monthsold healthy children (male or female) born at term after normal pregnancy Recording of medical history and physical examination reveal no abnormality The parent/legal guardian of the participating child must sign the written informed consent and agree to provide a blood sample taken from the child pre and postimmunization Exclusion criteria: Hypersensitivity to eggs, chicken proteins, polymyxin B, neomycin or any component of the vaccine Previous vaccination against influenza At time of enrollment, presentation of clinical symptoms of active infection and/or body temperature ≥38°C Confirmation or suspicion of immunosuppressed status (including cancer), or confirmation of immunodeficiency disease (congenital or acquired including HIV) Medical treatment (&gt;2 weeks) with immune suppressant or immune modulating drugs including systemic steroids during the last 3 months before immunization or at present, as follows: longterm oral prednisone or other equivalent steroid: ≥0.5mg/kg/day (note: administration of local or inhaled steroids before or during the study is allowed) Treatment with immunoglobulins or blood products during the last 3 months before immunization or such treatment scheduled during the study Participation in other clinical trials during the last 3 months before immunization or intention to participate during this study period At present or during the last 6 months before immunization: radiotherapy or treatment with cytotoxic drugs Other vaccination with a killed vaccine within 14 days before immunization or with an attenuated vaccine within 28 days before immunization (note: after subject inclusion vaccines of the immunization program for children are allowed upon the physician's discretion. However, immunization on the same day must be avoided) Family history of GuillainBarré Syndrome Severe congenital deficiency or disease Antecedent of neurological disease or epileptic attack Severe cardiopulmonary disease with possibility to influence the study result Disturbance of coagulation or under anticoagulant treatment, likely to be contraindicated to i.m. injection Suspected noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Virus</keyword>
	<keyword>Vaccination</keyword>
	<keyword>Immunisation</keyword>
</DOC>